References
- Ng PC , MurraySS, LevyS, VenterJC. An agenda for personalized medicine. Nature461(7265) , 724–726 (2009).
- Janssens AC , van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum. Mol. Genet.17(R2) , R166–R173 (2008).
- Chua EW , KennedyMA. Current state and future prospects of direct-to-consumer pharmacogenetics. Front. Pharmacol.3 , 152 (2012).
- Thompson MA , AbergJA, CahnP et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3) , 321–333 (2010).
- Hetherington S , McGuirkS, PowellG et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23(10) , 1603–1614 (2001).
- Mallal S , PhillipsE, CarosiG et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358(6) , 568–579 (2008).
- Saag M , BaluR, PhillipsE et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46(7) , 1111–1118 (2008).
- Anderson JL , AdamsCD, AntmanEM et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(18) , e426–e579 (2011).
- Siller-Matula JM , Delle-KarthG, LangIM et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J. Thromb. Haemost. 10 , 529–542 (2012).
- Teutsch SM , BradleyLA, PalomakiGE et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet. Med. 11(1) , 3–14 (2009).
- Holmes MV , PerelP, ShahT, HingoraniAD, CasasJP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA306(24) , 2704–2714 (2011).
- Glas AS , LijmerJG, PrinsMH, BonselGJ, BossuytPM. The diagnostic odds ratio: a single indicator of test performance. J. Clin. Epidemiol.56(11) , 1129–1135 (2003).
- Janssens AC , AulchenkoYS, ElefanteS, BorsboomGJ, SteyerbergEW, van Duijn CM. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet. Med.8(7) , 395–400 (2006).
- Regan MM , Leyland-JonesB, BouzykM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J. Natl Cancer Inst.104 , 441–451 (2012).
- SEARCH Collaborative Group, Link E, Parish S et al.SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8) , 789–799 (2008).
- Brunham LR , LansbergPJ, ZhangL et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3) , 233–237 (2012).
- Biernacka JM , McElroySL, CrowS et al. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J. Affect. Disord. 136 , e21–e29 (2012).
- Kato M , SerrettiA. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry15 , 473–500 (2010).
▪ Websites
- 23andMe. www.23andme.com (Accessed 1December2012)
- deCODEme.www.decodeme.com (Accessed 1December2012)
- YouScript.www.youscript.com/patients (Accessed 1December2012)
- GenePlanet. www.geneplanet.com (Accessed 1December2012)
- Theranostics Laboratory. www.theranostics.co.nz (Accessed 1December2012)
- United States Government Accountability Office. Direct-to-consumer genetic tests: Misleading test results are further complicated by deceptive marketing and other questionable practices. www.gao.gov/assets/130/125079.pdf (Accessed 1December2012)
- US FDA: Ziagen (abacavir sulfate), drug label, labeling revision 18–05–2012, reference ID: 3133159.www.accessdata.fda.gov/drugsatfda_docs/label/2012/020977s025,020978s029lbl.pdf (Accessed 1December2012)
- US FDA: Plavix (clopidogrel bisulphate), drug label, labeling revision 20–12–2011, reference ID: 3061125. www.accessdata.fda.gov/drugsatfda_docs/label/2011/020839s055lbl.pdf (Accessed 1December2012)